Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Medha Gayathri J. Pai, Deeptarup Biswas, Ayushi Verma & Sanjeeva Srivastava. (2023) A proteome-level view of brain tumors for a better understanding of novel diagnosis, prognosis, and therapy. Expert Review of Proteomics 0:0, pages 1-15.
Read now
Read now
Articles from other publishers (30)
Xiaoping Hu, Jingdun Xie, Yilin Yang, Ziyi Qiu, Weicheng Lu, Xudong Lin & Bingzhe Xu. (2023) Multi-Target Neural Differentiation (MTND) Therapeutic Cocktail to Suppress Brain Tumor. International Journal of Molecular Sciences 24:15, pages 12329.
Crossref
Crossref
Jingjing Wang, Yue Liu, Fengbo Liu, Shaoyan Gan, Shubham Roy, Ikram Hasan, Baozhu Zhang & Bing Guo. (2023) Emerging extracellular vesicle-based carriers for glioblastoma diagnosis and therapy. Nanoscale 15:26, pages 10904-10938.
Crossref
Crossref
N. S. Kuznetsova, S. V. Gurova, A. S. Goncharova, E. V. Zaikina, M. A. Gusareva & M. S. Zinkovich. (2023) Modern approaches to glioblastoma therapy. South Russian Journal of Cancer 4:1, pages 52-64.
Crossref
Crossref
Harpinder K. Brar, Jiney Jose, Zimei Wu & Manisha Sharma. (2022) Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery. Pharmaceutics 15:1, pages 59.
Crossref
Crossref
Shunichiro Miki, Tomoyuki Koga, Andrew M Mckinney, Alison D Parisian, Takahiro Tadokoro, Raghavendra Vadla, Martin Marsala, Robert F Hevner, Joseph F Costello & Frank Furnari. (2022)
TERT
promoter C228T mutation in neural progenitors confers growth advantage following telomere shortening
in vivo
. Neuro-Oncology 24:12, pages 2063-2075.
Crossref
Crossref
Valentina Bova, Alessia Filippone, Giovanna Casili, Marika Lanza, Michela Campolo, Anna Paola Capra, Alberto Repici, Lelio Crupi, Gianmarco Motta, Cristina Colarossi, Giulia Chisari, Salvatore Cuzzocrea, Emanuela Esposito & Irene Paterniti. (2022) Adenosine Targeting as a New Strategy to Decrease Glioblastoma Aggressiveness. Cancers 14:16, pages 4032.
Crossref
Crossref
Chaeyeong Kim, Gyeyeong Kong, Hyunji Lee, Quangdon Tran, Thuy-Trang T. Vo, So Hee Kwon, Jisoo Park, Seon-Hwan Kim & Jongsun Park. (2022) Scavenger receptor class F member 2 (SCARF2) as a novel therapeutic target in glioblastoma. Toxicological Research 38:2, pages 249-256.
Crossref
Crossref
Sajita Shah & Gina M. Sizemore. 2022. Stromal Signaling in Cancer. Stromal Signaling in Cancer
93
140
.
Atinderpal Kaur, Surbhi Sharma, Afeefa Noor, Shweta Dang & Sushama Talegaonkar. 2022. Nanocarriers for Drug-Targeting Brain Tumors. Nanocarriers for Drug-Targeting Brain Tumors
69
120
.
Dhananjay A. Chitale. 2022. Cancer Metastasis Through the Lymphovascular System. Cancer Metastasis Through the Lymphovascular System
3
14
.
Gong Peng, Yin Wang, Pengfei Ge, Christopher Bailey, Peng Zhang, Di Zhang, Zhaoli Meng, Chong Qi, Qian Chen, Jingtao Chen, Junqi Niu, Pan Zheng, Yang Liu & Yan Liu. (2021) The HIF1α-PDGFD-PDGFRα axis controls glioblastoma growth at normoxia/mild-hypoxia and confers sensitivity to targeted therapy by echinomycin. Journal of Experimental & Clinical Cancer Research 40:1.
Crossref
Crossref
Tapan Behl, Aditi Sharma, Lalit Sharma, Aayush Sehgal, Sukhbir Singh, Neelam Sharma, Gokhan Zengin, Simona Bungau, Mirela Marioara Toma, Daniela Gitea, Elena Emilia Babes, Claudia Teodora Judea Pusta & Adrian Gheorghe Bumbu. (2021) Current Perspective on the Natural Compounds and Drug Delivery Techniques in Glioblastoma Multiforme. Cancers 13:11, pages 2765.
Crossref
Crossref
Jean de Montigny, Alexandros Iosif, Lukas Breitwieser, Marco Manca, Roman Bauer & Vasileios Vavourakis. (2021) An in silico hybrid continuum-/agent-based procedure to modelling cancer development: Interrogating the interplay amongst glioma invasion, vascularity and necrosis. Methods 185, pages 94-104.
Crossref
Crossref
Farhana Akter, Brennan Simon, Nadine Leonie de Boer, Navid Redjal, Hiroaki Wakimoto & Khalid Shah. (2020) Pre-clinical tumor models of primary brain tumors: Challenges and opportunities. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, pages 188458.
Crossref
Crossref
Motomichi Fujita, Manabu Sasada, Takuya Iyoda & Fumio Fukai. (2020) Involvement of Integrin-Activating Peptides Derived from Tenascin-C in Cancer Aggression and New Anticancer Strategy Using the Fibronectin-Derived Integrin-Inactivating Peptide. Molecules 25:14, pages 3239.
Crossref
Crossref
Vilashini Rajaratnam, Mohammad Islam, Maixee Yang, Rachel Slaby, Hilda Ramirez & Shama Mirza. (2020) Glioblastoma: Pathogenesis and Current Status of Chemotherapy and Other Novel Treatments. Cancers 12:4, pages 937.
Crossref
Crossref
Muhibullah S. Tora, Pavlos Texakalidis, Stewart Neill, Jeremy Wetzel, Rima S. Rindler, Nathan Hardcastle, Purva P. Nagarajan, Andrey Krasnopeyev, Cristin Roach, Raphael James, Jeffrey N. Bruce, Peter Canoll, Thais Federici, John N. Oshinski & Nicholas M. Boulis. (2020) Lentiviral Vector Induced Modeling of High-Grade Spinal Cord Glioma in Minipigs. Scientific Reports 10:1.
Crossref
Crossref
Sorah Yoon, Xiwei Wu, Brian Armstrong, Nagy Habib & John J. Rossi. (2019) An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFRα Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma. Molecular Therapy - Nucleic Acids 14, pages 131-141.
Crossref
Crossref
Jeff Ehresman & Chetan Bettegowda. 2019. Comprehensive Overview of Modern Surgical Approaches to Intrinsic Brain Tumors. Comprehensive Overview of Modern Surgical Approaches to Intrinsic Brain Tumors
191
203
.
Amanda J. Harvey. 2019. Predictive Biomarkers in Oncology. Predictive Biomarkers in Oncology
167
182
.
Susmita Sil, Palsamy Periyasamy, Annadurai Thangaraj, Ernest T. Chivero & Shilpa Buch. (2018) PDGF/PDGFR axis in the neural systems. Molecular Aspects of Medicine 62, pages 63-74.
Crossref
Crossref
Natalia Papadopoulos & Johan Lennartsson. (2018) The PDGF/PDGFR pathway as a drug target. Molecular Aspects of Medicine 62, pages 75-88.
Crossref
Crossref
Keisuke Sumiyoshi, Hideto Koso & Sumiko Watanabe. (2018) Spontaneous development of intratumoral heterogeneity in a transposon‐induced mouse model of glioma. Cancer Science 109:5, pages 1513-1523.
Crossref
Crossref
Richard E Kast, Quentin A Hill, Didier Wion, Håkan Mellstedt, Daniele Focosi, Georg Karpel-Massler, Tim Heiland & Marc-Eric Halatsch. (2017) Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: Potential therapeutic benefit from dapsone, fenofibrate, and ribavirin. Tumor Biology 39:5, pages 101042831769979.
Crossref
Crossref
Yoko Ishii, Takeru Hamashima, Seiji Yamamoto & Masakiyo Sasahara. (2017) Pathogenetic significance and possibility as a therapeutic target of platelet derived growth factor. Pathology International 67:5, pages 235-246.
Crossref
Crossref
Surasak Phuphanich, Jeffrey Raizer, Marc Chamberlain, Paola Canelos, Rajesh Narwal, Shengyan Hong, Robert Miday, Minal Nade & Kevin Laubscher. (2016) Phase II study of MEDI-575, an anti-platelet-derived growth factor-α antibody, in patients with recurrent glioblastoma. Journal of Neuro-Oncology 131:1, pages 185-191.
Crossref
Crossref
Pratik Kanabur, Sujuan Guo, Cara M. Rodgers, Gary R. Simonds, Deborah F. Kelly, Robert G. Gourdie, Scott S. Verbridge & Zhi Sheng. (2016) Patient-derived glioblastoma stem cells respond differentially to targeted therapies. Oncotarget 7:52, pages 86406-86419.
Crossref
Crossref
Yin Xu, Kaiqiang Wang & Qin Yu. (2016) FRMD6 inhibits human glioblastoma growth and progression by negatively regulating activity of receptor tyrosine kinases. Oncotarget 7:43, pages 70080-70091.
Crossref
Crossref
Tracy T. Batchelor, Elizabeth R. Gerstner, Xiaobu Ye, Serena Desideri, Daniel G. Duda, David Peereboom, Glenn J. Lesser, Sajeel Chowdhary, Patrick Y. Wen, Stuart Grossman & Jeffrey G. Supko. (2016) Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma. Neuro-Oncology, pages now185.
Crossref
Crossref
Howard A. Fine. (2015) New Strategies in Glioblastoma: Exploiting the New Biology. Clinical Cancer Research 21:9, pages 1984-1988.
Crossref
Crossref